ATE535242T1 - Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie - Google Patents

Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie

Info

Publication number: ATE535242T1
Authority: AT; Austria
Prior art keywords: group; optionally substituted; transition; surgical treatment; medical composition
Prior art date: 2004-10-06

Application number

AT05790245T

Other languages

English (en)

Inventor

Yoshio Okubo

Tomoji Shimizu

Nobuhiko Arai

Yasuhiro Omori

Original Assignee

Kissei Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-06

Filing date

2005-10-04

Publication date

2011-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36142692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE535242(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-10-04 Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE535242T1 publication Critical patent/ATE535242T1/de

Links

230000007704 transition Effects 0.000 title abstract 3
206010020880 Hypertrophy Diseases 0.000 title 1
210000002307 prostate Anatomy 0.000 title 1
238000001356 surgical procedure Methods 0.000 title 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 2
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 2
125000002252 acyl group Chemical group 0.000 abstract 2
125000001931 aliphatic group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
230000002265 prevention Effects 0.000 abstract 2
238000002560 therapeutic procedure Methods 0.000 abstract 2
125000005041 acyloxyalkyl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
125000003387 indolinyl group Chemical class N1(CCC2=CC=CC=C12)* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Steroid Compounds (AREA)
Indole Compounds (AREA)

AT05790245T 2004-10-06 2005-10-04 Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie ATE535242T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2004294358		2004-10-06
JP2005160843		2005-06-01
PCT/JP2005/018356 WO2006038619A1 (ja)	2004-10-06	2005-10-04	前立腺肥大症に対する手術療法への移行予防用医薬組成物

Publications (1)

Publication Number	Publication Date
ATE535242T1 true ATE535242T1 (de)	2011-12-15

Family

ID=36142692

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05790245T ATE535242T1 (de)	2004-10-06	2005-10-04	Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie

Country Status (12)

Country	Link
US (1)	US20080090893A1 (de)
EP (1)	EP1806136B1 (de)
JP (1)	JPWO2006038619A1 (de)
KR (1)	KR20070059152A (de)
AT (1)	ATE535242T1 (de)
CA (1)	CA2582045C (de)
ES (1)	ES2378240T3 (de)
PL (1)	PL1806136T3 (de)
PT (1)	PT1806136E (de)
SI (1)	SI1806136T1 (de)
TW (1)	TWI377058B (de)
WO (1)	WO2006038619A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2009009230A (es) *	2007-02-28	2009-11-26	Kissei Pharmaceutical	Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
CN101754760A (zh) *	2007-07-20	2010-06-23	安斯泰来制药株式会社	用以改善伴随着前列腺肥大的下尿路症状的药物组合物
EP2181707A1 (de) *	2008-11-04	2010-05-05	Astellas Ireland Co., Ltd.	Kombinierte Verwendung eines alpha-adrenergischen Rezeptorantagonisten und eines Antimuskarinmittels
ES2471076T3 (es) *	2010-06-28	2014-06-25	Ratiopharm Gmbh	Compuestos de inclusión de silodoxina-ciclodextrina

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU9095998A (en) *	1997-09-22	1999-04-12	Kissei Pharmaceutical Co. Ltd.	Remedies for dysuria resulting from prostatic hypertrophy
ES2237515T3 (es) *	2001-09-14	2005-08-01	Schwarz Pharma Ag	Dispositivo de administracion transdermica para el tratamiento de trastornos del tracto urinario.
US20030225079A1 (en) *	2002-05-11	2003-12-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
UA78854C2 (en) *	2002-09-06	2007-04-25	Kissei Pharmaceutical	Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
BRPI0404050A (pt) *	2003-09-24	2005-06-14	Bioxell Spa	Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento
US20070167511A1 (en) *	2004-03-05	2007-07-19	Kissei Pharmaceutical Co,. Ltd.	Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder

2005
- 2005-10-04 EP EP05790245A patent/EP1806136B1/de not_active Expired - Lifetime
- 2005-10-04 JP JP2006539298A patent/JPWO2006038619A1/ja active Pending
- 2005-10-04 AT AT05790245T patent/ATE535242T1/de active
- 2005-10-04 CA CA2582045A patent/CA2582045C/en not_active Expired - Lifetime
- 2005-10-04 ES ES05790245T patent/ES2378240T3/es not_active Expired - Lifetime
- 2005-10-04 PL PL05790245T patent/PL1806136T3/pl unknown
- 2005-10-04 WO PCT/JP2005/018356 patent/WO2006038619A1/ja not_active Ceased
- 2005-10-04 SI SI200531474T patent/SI1806136T1/sl unknown
- 2005-10-04 PT PT05790245T patent/PT1806136E/pt unknown
- 2005-10-04 KR KR1020077008738A patent/KR20070059152A/ko not_active Ceased
- 2005-10-04 US US11/576,800 patent/US20080090893A1/en not_active Abandoned
- 2005-10-06 TW TW094134936A patent/TWI377058B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
US20080090893A1 (en)	2008-04-17
EP1806136A1 (de)	2007-07-11
WO2006038619A1 (ja)	2006-04-13
JPWO2006038619A1 (ja)	2008-05-15
TW200626143A (en)	2006-08-01
EP1806136A4 (de)	2008-03-12
PT1806136E (pt)	2012-03-08
CA2582045C (en)	2013-10-22
SI1806136T1 (sl)	2012-03-30
KR20070059152A (ko)	2007-06-11
CA2582045A1 (en)	2006-04-13
TWI377058B (en)	2012-11-21
ES2378240T3 (es)	2012-04-10
PL1806136T3 (pl)	2012-04-30
EP1806136B1 (de)	2011-11-30

Similar Documents

Publication	Publication Date	Title
MY141661A (en)	2010-05-31	17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20060971L (no)	2006-05-02	Pyridazinderivater og deres anvendelse som terapeutiske midler
BG66087B1 (bg)	2011-03-31	Хинолинонови производни като тирозин киназни инхибитори
NO20071042L (no)	2007-04-19	5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
EA200400073A1 (ru)	2004-08-26	Пирролопиримидины как ингибиторы протеинкиназы
ATE443043T1 (de)	2009-10-15	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
IL173032A0 (en)	2006-06-11	Pyridazine derivatives and their use as therapeutic agents
AU2003301020A1 (en)	2004-07-22	Isoquinolinone derivatives and their use as therapeutic agents
NO20051527L (no)	2005-03-22	3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer.
NO20021328L (no)	2002-05-21	Pyrazolopyrimidier som terapeutiske midler
MY133473A (en)	2007-11-30	Haterocyclic glycyl beta-alanine derivatives.
PT1263730E (pt)	2008-02-11	Derivados amina para o tratamento de apoptose
AU2002314914A1 (en)	2002-12-16	Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
AP2003002929A0 (en)	2003-12-31	Pyrrolopyrimidines as protein kinase inhibitors
DE60121461D1 (de)	2006-08-24	Kondensierte pyridoindolderivate
MXPA04003611A (es)	2004-07-30	Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
DE60031686D1 (de)	2006-12-14	Pyrazinone, diese verbindungen enthaltende zusammenstellungen
HK1046404A1 (zh)	2003-01-10	用作nmda受体拮抗剂的取代的吡咯烷-2，3，4-三酮-3-肟衍生物
NO20052699L (no)	2005-06-06	4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
ATE535242T1 (de)	2011-12-15	Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie
DE60034545D1 (de)	2007-06-06	Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
YU19302A (sh)	2004-11-25	4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
ATE425756T1 (de)	2009-04-15	Verwendung von carbamazepinderivaten zur behandlung von agitatio in demenspatienten
ATE465151T1 (de)	2010-05-15	4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
ATE519740T1 (de)	2011-08-15	Tetrahydroindolderivate zur behandlung von alzheimer-krankheit